By browsing our site you agree to our use of cookies. You will only see this message once. Find out more

Automated, real-time, label-free, biophysical assay platform for mode of action compound profiling to support our ongoing small molecule drug discovery efforts a the Drug Discovery Unit at the CRUK Manchester Institute (CRUK MI).

Voluntary ex ante transparency notice

Supplies

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1)Name and addresses
The University of Manchester
Oxford Road
Manchester
M13 9PL
United Kingdom
Contact person: Central Procurement Office
Telephone: +44 01612752160
E-mail:
NUTS code: UKD3

Internet address(es):

Main address: http://www.manchester.ac.uk/

Address of the buyer profile: http://www.procurement.manchester.ac.uk/

I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Education

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Automated, Real-time, Label-free, Biophysical Assay Platform.

Reference number: 2017/1253/ARLBP/SP
II.1.2)Main CPV code
38000000 - FG11
II.1.3)Type of contract
Supplies
II.1.4)Short description:

Automated, real-time, label-free, biophysical assay platform for mode of action compound profiling to support our ongoing small molecule drug discovery efforts a the Drug Discovery Unit at the CRUK Manchester Institute (CRUK MI).

II.1.6)Information about lots
This contract is divided into lots: no
II.1.7)Total value of the procurement (excluding VAT)
Lowest offer: 164 000.00 GBP / Highest offer: 165 000.00 GBP taken into consideration
II.2)Description
II.2.1)Title:
II.2.2)Additional CPV code(s)
38500000 - FG11
II.2.3)Place of performance
NUTS code: UKD3
Main site or place of performance:

CRUK Manchester Institute (CRUK MI), The University of Manchester.

II.2.4)Description of the procurement:

The high-quality comprehensive characterization of molecular interactions including kinetics, affinity, specificity, comparability, concentration, and thermodynamics. Detailed kinetic and thermodynamic profiling of compound-target interactions (kon, koff, KD, ΔH and ΔS) in a medium-throughput fashion.

II.2.5)Award criteria
II.2.11)Information about options
Options: no
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Negotiated procedure without prior publication
  • The works, supplies or services can be provided only by a particular economic operator for the following reason:
    • absence of competition for technical reasons
Explanation:

In addition to the critical sensitivity advantages, the platform offers some unique features which are not available with other SPR platforms. These include the ability to perform single cycle kinetics (SCK) in addition to the more classical multi-cycle kinetics (MCK). The former technique offers a rapid screening method which can be used to obtain a full kinetic / affinity characterization of small molecules without the need for surface regeneration. Also uniquely, the platform can be used to derive transition state thermodynamics from kinetic rate constants whereby the potential of enthalpy and entropy correlations associated with chemical modifications in a lead series can be specified enabling a more robust and reliable drug discovery process. 1 key advantage of SPR over the other biophysical techniques is its enhanced sensitivity. The platform has no lower molecular weight limit for the detection of organic molecules and therefore can be employed for very low molecular weight compound screening e.g. fragments. It also offer the largest kinetic space in relation to association and dissociation rates with the baseline noise of this machine set at an industry leading < 0.03 RU. Also, the ability to work with organic solvents up to 12 % DMSO.

IV.1.3)Information about framework agreement
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure

Section V: Award of contract/concession

Title:

Automated, Real-time, Label-free, Biophysical assay platform

V.2)Award of contract/concession
V.2.1)Date of conclusion of the contract/concession award decision:
14/03/2017
V.2.2)Information about tenders
The contract has been awarded to a group of economic operators: no
V.2.3)Name and address of the contractor/concessionaire
GE Healthcare Life Sciences
Little Chalfont, Amersham Place
Amersham
HP7 9NA
United Kingdom
NUTS code: UK
The contractor/concessionaire will be an SME: no
V.2.4)Information on value of the contract/lot/concession (excluding VAT)
Lowest offer: 164 000.00 GBP / Highest offer: 165 000.00 GBP taken into consideration
V.2.5)Information about subcontracting

Section VI: Complementary information

VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
The University of Manchester
Manchester
United Kingdom

Internet address:http://www.procurement.manchester.ac.uk/

VI.4.2)Body responsible for mediation procedures
VI.4.3)Review procedure
VI.4.4)Service from which information about the review procedure may be obtained
The University of Manchester
Oxford Road
Manchester
M13 9PL
United Kingdom

Internet address:http://www.procurement.manchester.ac.uk/

VI.5)Date of dispatch of this notice:
15/03/2017